| Literature DB >> 28911467 |
Asta Spadiene1, Nijole Savickiene2, Liudas Ivanauskas3, Valdas Jakstas2, Andrejs Skesters4, Alise Silova4, Hiliaras Rodovicius5.
Abstract
The prevalence of diabetes mellitus (DM) has dramatically increased in the past decade. Furthermore, increasing evidence from research shows that oxidative stress (OS) plays a crucial role in the pathogenesis of diabetes and in its complications. A search for ways to reduce oxidative damage has become the focus of interest for the majority of scientists. In this study, we determined the radical scavenging activity of single green tea constituents by using an on-line high performance liquid chromatography (HPLC)-2,2-diphenyl-1-picrylhydrazyl (DPPH) method and evaluated the antioxidant effects on type 2 diabetic patients by performing a double-blind, placebo-controlled study. Epigallocatechin gallate was identified as the most potent antioxidant, contributing approximately 50% of the total antioxidant capacity of green tea extract. We also found a statistically significant decrement of lipid peroxidation markers in patients treated with green tea extract after 9 months or after 18 months of follow-up. Overall, these findings are attractive for diabetic patients, helping them to keep a high level of performance and well-being, which ultimately may delay the time of disability and reduce mortality.Entities:
Keywords: Antioxidant; Diabetes mellitus; Green tea extract; HPLC; Oxidative stress
Year: 2014 PMID: 28911467 PMCID: PMC9355006 DOI: 10.1016/j.jfda.2014.04.001
Source DB: PubMed Journal: J Food Drug Anal Impact factor: 6.157
Fig. 1(A) High performance liquid chromatography (HPLC); and (B) UV–2,2-diphenyl-1-picrylhydrazyl (DPPH) chromatograms of the Extract Camellia sinensis. Peaks: 1. epigallocatechin, 2. catechin, 3. epicatechin, 4. epigallocatechin-3-gallate, and 5. epicatechin-3-gallate.
Comparison of the investigated parameters between groups at baseline, after 9 months, and after 18 months.
| Group | At baseline (I) | After 9 mo (II) | After 18 mo (III) |
| |
|---|---|---|---|---|---|
| SOD (U/g Hb) | ECs | 1360.75 ± 140.9 | 1450.05 ± 170.6 | 1410.75 ± 131,6 | I–II |
| Placebo | 1406.20 ± 139.5 | 1487.24 ± 128.8 | 1464.04 ± 143.0 | I–II | |
|
| NS | NS | NS | ||
| CAT (k/g Hb) | ECs | 229.05 ± 74.1 | 219.11 ± 61.5 | 237.82 ± 65.3 | |
| Placebo | 211.75 ± 60.1 | 242.48 ± 68.5 | 206.04 ± 79.4 | II–III | |
|
| NS | NS | NS | ||
| GPx (U/L) | ECs | 6971.05 ± 2006.5 | 7586.80 ± 2865.9 | 6561.19 ± 1560.0 | |
| Placebo | 6398.28 ± 1964.3 | 7311.70 ± 2024.7 | 6787.78 ± 1670.7 | I–II | |
|
| NS | NS | NS | ||
| Vitamin E (μg/mL) | ECs | 13.41 ± 4.3 | 13.58 ± 4.7 | 13.96 ± 5.2 | |
| Placebo | 15.81 ± 4.4 | 13.18 ± 3.9 | 12.03 ± 3.3 | I–II | |
|
| NS | NS | NS | ||
| TAS (mmol/L) | ECs | 1.64 ± 0.16 | 1.67 ± 0.18 | 1.66 ± 0.12 | |
| Placebo | 1.54 ± 0.17 | 1.67 ± 0.19 | 1.60 ± 0.17 | ||
|
| NS | NS | NS | ||
| Se (μg/L) | ECs | 78.50 ± 16.76 | |||
| Placebo | 77.52 ± 15.79 | ||||
|
| NS | ||||
| MDA (μM) | ECs | 1.81 ± 0.66 | 1.51 ± 0.40 | 1.62 ± 0.80 | I–II |
| Placebo | 1.84 ± 1.28 | 1.68 ± 0.51 | 1.89 ± 1.20 | ||
|
| NS | NS | NS | ||
| HNE (μM) | ECs | 4.36 ± 3.46 | 4.58 ± 3.22 | 4.54 ± 1.95 | |
| Placebo | 6.51 ± 5.00 | 5.69 ± 2.64 | 5.01 ± 3.14 | ||
|
| NS | NS | NS | ||
| MDA ± HNE (μM) | ECs | 5.99 ± 3.73 | 6.21 ± 3.10 | 6.16 ± 2.29 | |
| Placebo | 7.77 ± 5.24 | 7.37 ± 2.65 | 6.92 ± 3.62 | ||
|
| NS | NS | NS | ||
| LOOH (μM) | ECs | 7.80 ± 3.7 | 5.88 ± 2.9 | 7.30 ± 5.6 | |
| Placebo | 8.58 ± 5.4 | 6.95 ± 3.4 | 7.26 ± 4.2 | ||
|
| NS | NS | NS |
CAT = catalase; ECs = Extract Camellia sinensis; GPx = glutathione peroxidase; HNE = 4-hydroxy-2-nonenal; LOOH = lipid hydroperoxides; MDA = malondialdehyde; Se = Selenium; SOD = superoxide dismutase; TAS = total antioxidant status.